Enanta Pharmaceuticals, Inc - ENTA STOCK NEWS

Enanta Pharmaceuticals has initiated the SPRINT clinical trial for EDP-235, a 3CL protease inhibitor targeting COVID-19. This Phase 2 study evaluates the safety and effectiveness of EDP-235 in non-hospitalized adults with mild to moderate symptoms. Previous Phase 1 results indicated promising safety and potent antiviral activity against the Omicron variant. EDP-235 aims to provide a convenient once-daily treatment option. The trial will enroll approximately 200 participants, with data expected to be reported in the first half of 2023.

Enanta Pharmaceuticals (NASDAQ: ENTA) announced promising preclinical data for its COVID-19 treatment, EDP-235, presented at IDWeek 2022 in Washington, DC. The data indicates EDP-235 effectively penetrates target tissues, including macrophages and monocytes, potentially mitigating cytokine storms in high-risk patients. Enanta plans to initiate a Phase 2 study of EDP-235 this quarter. The drug showed favorable safety and pharmacokinetics in earlier studies, positioning it as a potential best-in-class antiviral.

Enanta Pharmaceuticals (NASDAQ:ENTA) has initiated its Phase 1 clinical trial for EDP-323, an oral L-protein inhibitor targeting respiratory syncytial virus (RSV). This milestone follows promising preclinical data indicating EDP-323's effectiveness across RSV genotypes. The trial will enroll around 80 healthy participants to assess safety and pharmacokinetics, including randomized doses of EDP-323 and a placebo. RSV poses significant health risks, especially in young children and older adults. With EDP-323, Enanta aims to enhance its RSV treatment portfolio while potential benefits for patients are anticipated.

Enanta Pharmaceuticals (NASDAQ:ENTA) has initiated a Phase 2b study to assess the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults at high risk of complications from acute respiratory syncytial virus (RSV) infection. The study will involve approximately 180 participants treated with EDP-938 or placebo over 5 days, with evaluations made for 28 days post-treatment. Previous studies indicated EDP-938's ability to significantly reduce RSV RNA levels and its favorable safety profile, supporting its potential for optimal clinical benefit.

Enanta Pharmaceuticals (NASDAQ: ENTA) announced promising preclinical data on EDP-323, a novel non-nucleoside RSV L-inhibitor, and advancements in virology methods for RSV and hMPV research. Presented at the 12th International RSV Symposium, EDP-323 showed potent inhibition of RSV replication in various models, including a mouse infection model that demonstrated improved lung histopathology. The company's research is supported by royalties from its collaboration with AbbVie on hepatitis C treatments, aiding the advance of its pipeline for respiratory viral infections.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced new preclinical data for its respiratory syncytial virus (RSV) program, set to be presented at the 12th International RSV Symposium from September 29 to October 2, 2022, in Belfast, UK. Highlights include an oral presentation titled “EDP-323, a Novel L-Protein Inhibitor, for the Treatment of RSV” scheduled for October 1, and multiple poster presentations on September 30. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, funded by royalties from hepatitis C virus products.

Enanta Pharmaceuticals (NASDAQ:ENTA) announced new preclinical data for EDP-235, its oral coronavirus protease inhibitor aimed at treating COVID-19, to be presented at IDWeek 2022 from October 19-23, 2022, in Washington, DC. An oral presentation is scheduled for October 21, 2022, at 12:15 PM ET, discussing EDP-235's potential to mitigate cytokine storms in high-risk COVID-19 patients. Enanta continues its focus on small molecule drugs for viral infections and liver diseases, supported by royalties from its collaboration with AbbVie on hepatitis C virus products.

Enanta Pharmaceuticals (NASDAQ: ENTA), a biotechnology company specializing in small molecule drugs for viral infections and liver diseases, will feature CEO Jay R. Luly, Ph.D., at two investor conferences in September 2022. He will present at the Wells Fargo Healthcare Conference on September 8 at 3:10 p.m. ET, followed by a fireside chat at the Baird Global Healthcare Conference on September 13 at 9:40 a.m. ET. Live webcasts will be available on Enanta’s website, with replays accessible for 30 days after the events.

Enanta Pharmaceuticals reported fiscal Q3 2022 revenue of $19.5 million, primarily from royalties on AbbVie's MAVYRET®, a decline from $21.6 million in Q3 2021. R&D expenses decreased to $39.1 million from $47.0 million, while G&A expenses rose to $12.9 million from $8.5 million. The net loss was $31.7 million ($1.53 per share), compared to $24.0 million ($1.19 per share) in the previous year. Enanta plans to initiate Phase 2 studies for its COVID-19 treatment EDP-235 and RSV treatment EDP-938 in Q4 2022.